Clinical Trials Browser

Has announcements × Abiraterone Acetate × Genitourinary × Clear all

NCT04497844 2026-05-11

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT03748641 2026-05-08

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Phase 3 Active not recruiting

895 enrolled 19 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02975934 2025-07-25

TRITON3

Phase 3 Completed

405 enrolled 34 charts 1 FDA

Metastatic Castration Resistant Prostate Cancer

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Phase 3 Completed

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer